106
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Cardiohepatic syndrome and its prognostic predictive ability in patients with pulmonary arterial hypertension

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, & ORCID Icon show all
Pages 290-298 | Received 11 Feb 2023, Accepted 12 Jun 2023, Published online: 28 Jun 2023

References

  • Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119. doi: 10.1093/eurheartj/ehv317.
  • Poelzl G, Auer J. Cardiohepatic syndrome. Curr Heart Fail Rep. 2015;12(1):68–78. doi: 10.1007/s11897-014-0238-0.
  • Laribi S, Mebazaa A. Cardiohepatic syndrome: liver injury in decompensated heart failure. Curr Heart Fail Rep. 2014;11(3):236–240. doi: 10.1007/s11897-014-0206-8.
  • Luo C, Wu W, Wu C, et al. Liver dysfunction in idiopathic pulmonary arterial hypertension: prevalence, characteristics and prognostic significance, a retrospective cohort study in China. BMJ Open. 2021;11(9):e045165. doi: 10.1136/bmjopen-2020-045165.
  • Xu XQ, Lv ZC, Liu QQ, et al. Direct bilirubin: a new risk factor of adverse outcome in idiopathic pulmonary arterial hypertension. Int J Cardiol. 2017;228:895–899. doi: 10.1016/j.ijcard.2016.11.036.
  • Lu GH, Gong SG, Li C, et al. Prognostic value of gamma-glutamyl transferase in male patients with idiopathic pulmonary arterial hypertension. Front Cardiovasc Med. 2020;7:580908. doi: 10.3389/fcvm.2020.580908.
  • Takeda Y, Takeda Y, Tomimoto S, et al. Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension. BMC Pulm Med. 2010;10:22. doi: 10.1186/1471-2466-10-22.
  • Stepnowska E, Lewicka E, Dąbrowska-Kugacka A, et al. Predictors of poor outcome in patients with pulmonary arterial hypertension: a single center study. PLOS One. 2018;13(4):e0193245. doi: 10.1371/journal.pone.0193245.
  • ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–117. Erratum in: Am J Respir Crit Care Med. 2016;193:1185.
  • Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23(7):685–713. doi: 10.1016/j.echo.2010.05.010.
  • Stolz L, Orban M, Besler C, et al. Cardiohepatic syndrome is associated with poor prognosis in patients undergoing tricuspid transcatheter edge-to-edge valve repair. JACC Cardiovasc Interv. 2022;15(2):179–189. doi: 10.1016/j.jcin.2021.10.033.
  • Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. Chest. 2019;156(2):323–337. doi: 10.1016/j.chest.2019.02.004.
  • Benza RL, Kanwar MK, Raina A, et al. Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL lite 2, for use in patients with pulmonary arterial hypertension. Chest. 2021;159(1):337–346. doi: 10.1016/j.chest.2020.08.2069.
  • Megalla S, Holtzman D, Aronow WS, et al. Predictors of cardiac hepatopathy in patients with right heart failure. Med Sci Monit. 2011;17(10):CR537–CR541. doi: 10.12659/msm.881977.
  • van Deursen VM, Damman K, Hillege HL, et al. Abnormal liver function in relation to hemodynamic profile in heart failure patients. J Card Fail. 2010;16(1):84–90. doi: 10.1016/j.cardfail.2009.08.002.
  • Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation. 2010;122(2):164–172. doi: 10.1161/CIRCULATIONAHA.109.898122.
  • Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry. Chest. 2010;137(2):376–387. doi: 10.1378/chest.09-1140.
  • Dimopoulos K, Wort SJ, Gatzoulis MA. Pulmonary hypertension related to congenital heart disease: a call for action. Eur Heart J. 2014;35(11):691–700. doi: 10.1093/eurheartj/eht437.
  • Kaymaz C, Mutlu B, Küçükoğlu MS, et al. Preliminary results from a nationwide adult cardiology perspective for pulmonary hypertension: registry on clinical outcome and survival in pulmonary hypertension groups (SIMURG). Anatol J Cardiol. 2017;18:242–250.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.